10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



Anti-Complement Factor D Reference Antibody (lampalizumab)

Recombinant Antibody Catalog # APR10146

Product Information

Application FC, Kinetics, Animal Model

Primary Accession P00746

Reactivity Human, Rabbit
Clonality Monoclonal

Isotype IgG1 **Calculated MW** 27033

Additional Information

Target/Specificity Complement Factor D

Endotoxin

Conjugation Unconjugated

Expression system CHO Cell

Format Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

Protein Information

Name CFD (HGNC:2771)

Synonyms DF, PFD


Function Serine protease that initiates the alternative pathway of the complement

system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324, PubMed:9748277). In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3 (PubMed:21205667, PubMed:23263763, PubMed:6760474, PubMed:874334). The alternative


PubMed:<u>22362762</u>, PubMed:<u>6769474</u>, PubMed:<u>874324</u>). The alternative complement pathway acts as an amplification loop that enhances

complement activation by mediating the formation of C3 and C5 convertases (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324). Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway (PubMed:21205667, PubMed:6769474, PubMed:874324, PubMed:9748277).


Images



Anti-Complement Factor D Reference Antibody (lampalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Complement Factor D Reference Antibody (lampalizumab)is more than 99.38% ,determined by SEC-HPLC.



Immobilized human Complement Factor D, Fc at 2 µg/mL can bind Anti-Complement Factor D Reference Antibody (lampalizumab),EC50=0.02371 µg/mL

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.